Comparative analysis of treatment outcomes and risk factors associated with different combination antimicrobial regimens in patients with multidrug-resistant Acinetobacter baumannii pneumonia.

Meng Xu, Mingxing Liu, Xuebin Tang, Xiaoying Wu

Abstract readComparative Study

In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Meng XuClinical Pharmacology, Affiliated Hospital of Qinghai University, Xining, Qinghai, China.

Mingxing LiuDepartment of Emergency and Critical Care, Jiading Branch of Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Xuebin TangDepartment of Respiratory and Critical Care Medicine, Tongren People's Hospital, Tongren, Guizhou, China.

Xiaoying WuDepartment of Emergency Medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multidrug-resistant Objective: To compare the efficacy of different antibacterial regimens in MDRAB pneumonia and determine independent risk factors for 28-day all-cause mortality. Methods: This single-center retrospective cohort study included 142 MDRAB pneumonia patients from February 2022 to February 2025. Patients were divided into three groups: Group A, sulbactam-containing combinations (n = 63); Group B, polymyxins + tigecycline (n = 45); Group C, other regimens (n = 34). Outcomes included bacterial resistance patterns, 28-day mortality, dynamic PCT and CRP levels, APACHE II and SOFA scores, and lymphocyte subsets. Multivariate logistic regression identified mortality predictors. Results: Group A showed the lowest resistance to cefoperazone/sulbactam (30.16%) and the highest sensitivity (71.43%, both P< 0.05). Group B had the highest tigecycline resistance (31.11%). The 28-day mortality rates were 39.68% (A), 60.00% (B), and 64.71% (C) (P = 0.028). Independent mortality predictors were APACHE II, SOFA, and CD4+/CD8+ ratio (all P< 0.01). On day 7, Group A had the lowest PCT, while Group C showed the smallest declines in PCT and CRP. Group A exhibited the highest CD4+/CD8+ ratio. Conclusion: Sulbactam-based combination therapy was associated with improved pathogen clearance and survival in this retrospective cohort. Mortality is closely linked to initial disease severity and early organ dysfunction. Dynamic changes in PCT and CD4+/CD8+ ratio have significant prognostic value.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialPneumonia, BacterialAgedAged, 80 and overDrug Therapy, CombinationFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedPolymyxinsRetrospective StudiesRisk FactorsAnti-Bacterial AgentsPolymyxinsSulbactamTigecyclineantibiotic resistancehospital-acquired pneumoniamortality ratemultidrug-resistant Acinetobacter baumanniirisk factors

Identifiers

PMID42404764

DOI10.3389/fcimb.2026.1819679

PMCPMC13328476

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.